Type II diabetes mellitus is associated with a reduced risk of cholangiocarcinoma in patients with biliary tract diseases

International Journal of Cancer

Volumn 136, Issue 10, 2015, Pages 2409-2417

  Tsai, Ming Shian ^a   Lee, Po Huang ^a   Lin, Cheng Li ^b,c   Peng, Chiao Ling ^d   Kao, Chia Hung ^b,c  

^a I SHOU UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

biliary tract diseases; cholangiocarcinoma; diabetes mellitus; nationwide cohort study

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL LIVER CIRRHOSIS; ALCOHOLISM; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CANCER INCIDENCE; CANCER RISK; CHOLANGITIS; CHOLECYSTECTOMY; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC HEPATITIS; COHORT ANALYSIS; COMMON BILE DUCT CYST; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; INCOME; LIVER CIRRHOSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIABLE COX PROPORTIONAL HAZARDS REGRESSION MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; SEX RATIO; TAIWAN; URBANIZATION; BILE DUCT NEOPLASMS; BILIARY TRACT DISEASES; CHOLANGIOCARCINOMA; COMPLICATION; DIABETES MELLITUS, TYPE 2; INTRAHEPATIC BILE DUCT; MIDDLE AGED; PATHOLOGY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT DISEASES; CHOLANGIOCARCINOMA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 84924301407     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29292     Document Type: Article

References (44)

1. Rizvi S, Gores GJ,. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 2013; 145: 1215-29.
2. Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extra-hepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006; 98: 873-5.
3. Khan SA, Davidson BR, Goldin RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-69.
4. Everhart JE, Ruhl CE,. Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-44.
5. Tyson GL, El-Serag HB,. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-84.
6. Welzel TM, Mellemkjaer L, Gloria G, et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120: 638-41.
7. Chen YK, Yeh JH, Lin CL, et al. Cancer risk in patients with cholelithiasis and after cholecystectomy: a nationwide cohort study. J Gastroenterol 2014; 49: 923-31.
8. Nordenstedt H, Mattsson F, El-Serag H, et al. Gallstones and cholecystectomy in relation to risk of intra- and extra-hepatic cholangiocarcinoma. Br J Cancer 2012; 106: 1011-15.
9. Tsai MS, Lin WH, Hsu WM, et al. Clinicopathological feature and surgical outcome of choledochal cyst in different age groups: the implication of surgical timing. J Gastrointest Surg 2008; 12: 2191-5.
10. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-8.
11. Sripa B, Pairojkul C,. Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol 2008; 24: 349-56.
12. Hung SC, Liao KF, Lai SW, et al. Risk factors associated with symptomatic cholelithiasis in Taiwan: a population-based study. BMC Gastroenterol 2011; 11: 111.
13. Chapman BA, Wilson IR, Frampton CM, et al. Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci 1996; 41: 2222-8.
14. De Santis A, Attili AF, Ginanni Corradini S, et al. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 1997; 25: 787-90.
15. Ludvigsson JF, Bergquist A, Montgomery SM, et al. Risk of diabetes and cardiovascular disease in patients with primary sclerosing cholangitis. J Hepatol 2014; 60: 802-8.
16. Tsai MS, Li YF, Lin CL, et al. Long-term risk of acute coronary syndrome in patients with cholangitis: a 13-year nationwide cohort study. Eur J Intern Med 2014; 25: 444-8.
17. Liang JA, Sun LM, Yeh JJ, et al. Malignancies associated with systemic lupus erythematosus in Taiwan: a nationwide population-based cohort study. Rheumatol Int 2012; 32: 773-8.
18. Yu YH, Liao CC, Hsu WH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol 2011; 6: 32-7.
19. Cheng CL, Kao YH, Lin SJ, et al. Validation of the national health insurance research database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20: 236-42.
20. Kang JH, Chen YH, Lin HC,. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010; 69: 1165-8.
21. Chang JS, Tsai CR, Chen LT,. Medical risk factors associated with cholangiocarcinoma in Taiwan: a population-based case-control study. PLoS One 2013; 8: e69981.
22. Grainge MJ, West J, Solaymani-Dodaran M, et al. The antecedents of biliary cancer: a primary care case-control study in the United Kingdom. Br J Cancer 2009; 100: 178-80.
23. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-6.
24. Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008; 103: 1716-20.
25. Zhou YM, Yin ZF, Yang JM, et al. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14: 632-5.
26. Shaib YH, El-Serag HB, Nooka AK, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-21.
27. Yamamoto S, Kubo S, Hai S, et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95: 592-5.
28. Söreide K, Körner H, Havnen J, et al. Bile duct cysts in adults. Br J Surg 2004; 91: 1538-48.
29. Hsing AW, Sakoda LC, Rashid A, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Res 2008; 68: 6442-52.
30. Chaiteerakij R, Yang JD, Harmsen WS, et al. Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk. Hepatology 2013; 57: 648-55.
31. Lo SF, Chang SN, Muo CH, et al. Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer 2013; 132: 182-8.
32. De Santis A, Attili AF, Ginanni Corradini S, et al. Gallstones and diabetes: a case-control study in a free-living population sample. Hepatology 1997; 25: 787-90.
33. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-8.
34. de Leon MP, Ferenderes R, Carulli N,. Bile lipid composition and bile acid pool size in diabetes. Am J Dig Dis 1978; 23: 710-16.
35. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010; 52: 1455-64.
36. Alpini G, Ueno Y, Glaser SS, et al. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes. Hepatology 2001; 34: 868-76.
37. Holzinger F, Z'graggen K, Büchler MW,. Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann Oncol 1999; 10 (Suppl 4): 122-6.
38. Kinami Y, Ashida Y, Gotoda H, et al. Promoting effects of bile acid load on the occurrence of cholangiocarcinoma induced by diisopropanolnitrosamine in hamsters. Oncology 1993; 50: 46-51.
39. Yoon JH, Werneburg NW, Higuchi H, et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 2002; 62: 6500-5.
40. Yoon JH, Higuchi H, Werneburg NW, et al. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 2002; 122: 985-93.
41. Reveille RM, Van Stiegmann G, Everson GT,. Increased secondary bile acids in a choledochal cyst. Possible role in biliary metaplasia and carcinoma. Gastroenterology 1990; 99: 525-7.
42. Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010; 33: 322-6.
43. Blechacz B1, Komuta M, Roskams T, et al. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 512-22.
44. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-62.